Boehringer Ingelheim Animal Health has launched a new vaccine against Marek’s Disease.
PREVEXXION RN is licensed for use in day old broilers, layers and breeders. The new RN1250 PREVEXXION strain has been developed by taking the best traits from three different existing strains of MDV to create the first hybrid, next generation, vaccine against Marek’s Disease.
PREVEXXION RN can be combined with VAXXITEK HVT+IBD resulting in a unique vaccine that provides protection against MD and infectious bursal disease (IBD/Gumboro).
The vaccines are available in ampoules of 1000 and 2000 doses, stored frozen in liquid nitrogen. Jerôme Baudon, Head of Poultry in Boehringer Ingelheim, said: “Our PREVEXXION® RN range provides value through innovation to poultry producers looking for continuous live production productivity improvement and effective protection in the face of Marek’s Disease challenge. Field and lab experiments conducted worldwide demonstrated its efficacy and early, long-lasting and robust protection through the lifespan of the birds, and against very virulent Marek’s Disease challenge.”